Correction of metabolic disorders and eating pathology in patients with obesity receiving combination of Reduksin® (sibutramine+MCC) and Metforminum as part of All-Russian observational program «PrimaVera»
AbstractThe prevalence of obesity and overweight has grown by an average of 75 percent over the past decade and now is estimated as 1.7 billion people. The combination of metabolic and hemodynamic abnormalities with abdominal obesity type is known as “metabolic syndrome”. The aim of this study is to evaluate the effect of Reduxine® and metformin combination therapy over weight, glucose and lipids metabolism in obese patients who are participating in All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice – «PrimaVera» in the city of Tver.
Keywords:obesity, metabolic syndrome, sibutramine, PrimaVera, Reduxin®, metformin
Endocrinology: News, Opinions, Training. 2015; (2): 44–48.